Greenshoe fully exercised; deal funds development of PX-866 and ONT-10
By Devika Patel
Knoxville, Tenn., April 3 - Oncothyreon Inc. said it settled a $54.05 million public offering of stock. The offering was announced March 28 and priced for $47 million with a $7.05 million greenshoe on March 29.
The company sold 13,512,500 common shares at $4.00 per share. The price per share reflects an 8.05% discount to the March 21 closing share price of $4.35.
Of the shares, 1,762,500 were part of the fully exercised greenshoe.
Cowen and Co., LLC was the book-running manager, and Stifel, Nicolaus & Co., Inc. was the co-manager.
Proceeds will be used for development of PX-866, Oncothyreon's irreversible pan-isoform PI-3 kinase inhibitor, and ONT-10, Oncothyreon's proprietary follow-on vaccine to Stimuvax.
Oncothyreon is a Seattle biotechnology company.
| Issuer: | Oncothyreon Inc.
|
| Issue: | Common stock
|
| Amount: | $54.05 million (including $7.05 million greenshoe)
|
| Shares: | 13,512,500
|
| Price: | $4.00
|
| Warrants: | No
|
| Bookrunner: | Cowen and Co., LLC
|
| Announcement date: | March 28
|
| Pricing date: | March 29
|
| Settlement date: | April 3
|
| Stock symbol: | Nasdaq: ONTY
|
| Stock price: | $4.35 at close March 19
|
| Market capitalization: | $184.92 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
